| 股份代號: | 01276 | | --- | --- | | 上市法國名稱: | 江蘇恒瑞醫藥股份有限公司 - H股 | | 日期 (日 / 月 / 年): | 02/11/2025 - 02/12/2025 | | 表格序號 | 大股東/董事/最高行政人員名稱作出披露的 買入 / 費出或涉及的 每股的平均價 | | | | 持有權益的股份數目 佔已發行的 有關事件的日期 | | | --- | --- | --- | --- | --- | --- | --- | | | | 原因 | 股份數目 | | ( 請參閱上述 * 註 | 有投票權股 (日 / 月 / 年) | | | | | | | | 份百分比 | | | | | | | | ( % ) | | CS20251201E00011 | 422,400(L) GIC Private Limited | 1101(L) | | HKD 74.9550 | 59.462.200(L) | 23.03(L)27/11/2025 | 格隆汇12月2日丨根据联交所最新权益披露资料显示，2025年11月27日，恒瑞医药(01276.HK)获GIC Pri ...

智通财经APP获悉，香港联交所最新资料显示，11月27日，GIC Private Limited增持恒瑞医药 (01276)42.24万股，每股作价74.955港元，总金额约为3166.1万港元。增持后最新持股数目为5946.22万 股，最新持股比例为23.03%。 ...

Core Insights - The article highlights the top and bottom AH premium rates for various stocks as of December 1, with Northeast Electric (00042) leading with a premium rate of 881.82% [1] - The article also lists the stocks with the highest and lowest deviation values, indicating significant discrepancies between their A-shares and H-shares [1] Summary of Top AH Premium Rates - Northeast Electric (00042) has the highest AH premium rate at 881.82%, followed by Hongye Futures (03678) at 274.55% and Sinopec Oilfield Service (01033) at 269.74% [1] - The top ten stocks with high premium rates include Zhejiang Shibao (01057) at 261.98% and Chenming Paper (01812) at 245.83% [1] Summary of Bottom AH Premium Rates - The stocks with the lowest AH premium rates include Ningde Times (03750) at -5.03%, China Merchants Bank (03968) at -1.36%, and Heng Rui Medicine (01276) at 1.50% [1] - Other notable mentions in the bottom list include Weichai Power (02338) at 6.45% and Midea Group (00300) at 7.66% [1] Summary of Deviation Values - The stocks with the highest deviation values are Guanghe Communication (00638) at 31.56%, Dazhong Public Utilities (01635) at 23.38%, and Beijing Jingcheng Machinery Electric (00187) at 20.11% [1] - Conversely, the stocks with the lowest deviation values include Jiangsu Ninghu Expressway (00177) at -13.73%, Junsheng Electronics (00699) at -12.81%, and China Life (02628) at -11.45% [1]

Core Insights - The top three companies with the highest short positions as of November 21 are Vanke Enterprises (02202), COSCO Shipping Holdings (01919), and Heng Rui Medicine (01276), with short ratios of 19.60%, 16.49%, and 16.36% respectively [1][2] Summary by Category Top Short Positions - Vanke Enterprises (02202): Previous short position of 390 million shares, current short position of 433 million shares, resulting in a short ratio of 19.60% [2] - COSCO Shipping Holdings (01919): Maintained a short position of 475 million shares, with a short ratio of 16.49% [2] - Heng Rui Medicine (01276): Previous short position of 40.39 million shares, current short position of 42.24 million shares, leading to a short ratio of 16.36% [2] Largest Increases in Short Positions - China Hongqiao Group (01735): Increased short ratio from 0.04% to 2.61%, an increase of 2.58% [2][3] - Vanke Enterprises (02202): Increased short ratio from 17.68% to 19.60%, an increase of 1.92% [2][3] - Dongfang Electric (01072): Increased short ratio from 10.21% to 11.66%, an increase of 1.45% [2][3] Largest Decreases in Short Positions - Contemporary Amperex Technology Co., Ltd. (03750): Decreased short ratio from 13.64% to 10.74%, a decrease of 2.90% [3][4] - Sanhua Intelligent Controls (02050): Decreased short ratio from 10.21% to 8.93%, a decrease of 1.28% [3][4] - GCL-Poly Energy Holdings Limited (03800): Decreased short ratio from 8.86% to 7.67%, a decrease of 1.18% [3][4]

Core Insights - The article highlights the top and bottom AH share premium rates as of November 28, with Northeast Electric (00042) leading at 864.29% and CATL (03750) at -5.29% [1][2][3] Group 1: Top AH Share Premium Rates - Northeast Electric (00042) has the highest premium rate of 864.29%, with H-share priced at HKD 0.280 and A-share at CNY 2.25 [2] - Hongye Futures (03678) follows with a premium rate of 270.78%, H-share at HKD 3.320 and A-share at CNY 10.28 [2] - Sinopec Oilfield Service (01033) ranks third with a premium rate of 268.92%, H-share at HKD 0.740 and A-share at CNY 2.28 [2] Group 2: Bottom AH Share Premium Rates - CATL (03750) has the lowest premium rate at -5.29%, with H-share priced at HKD 472.000 and A-share at CNY 373.2 [3] - China Merchants Bank (03968) has a premium rate of -1.61%, H-share at HKD 52.300 and A-share at CNY 42.96 [3] - Heng Rui Medicine (01276) shows a premium rate of 0.75%, H-share at HKD 73.800 and A-share at CNY 62.07 [3] Group 3: Top AH Share Deviation Values - Guanghe Tong (00638) has the highest deviation value at 23.08%, with a premium rate of 95.88% [4] - Dazhong Public Utilities (01635) follows with a deviation value of 22.85% and a premium rate of 130.91% [4] - Shandong Xinhua Pharmaceutical (00719) ranks third with a deviation value of 20.46% and a premium rate of 197.76% [4] Group 4: Bottom AH Share Deviation Values - GAC Group (02238) has the lowest deviation value at -15.57%, with a premium rate of 167.63% [5] - China Southern Airlines (01055) shows a deviation value of -12.01% and a premium rate of 54.08% [5] - Jiangsu Ninghu Highway (00177) has a deviation value of -10.78% with a premium rate of 55.94% [5]

Group 1 - Morgan Stanley increased its stake in Heng Rui Medicine (01276) by 1.770645 million shares at an average price of 69.65 HKD per share, totaling approximately 123 million HKD [1] - After the increase, Morgan Stanley's total shareholding in Heng Rui Medicine is approximately 20.848 million shares, representing a holding percentage of 8.07% [1]

Core Viewpoint - Heng Rui Medicine (01276.HK) has received approval from the National Medical Products Administration for multiple clinical trial applications, indicating a significant step forward in its drug development pipeline [1] Group 1: Company Developments - The company and its subsidiaries, including Suzhou Shengdiya Biopharmaceutical Co., Ltd., Shanghai Heng Rui Medicine Co., Ltd., and Shanghai Shengdi Medicine Co., Ltd., have been granted clinical trial approval for several products [1] - The approved products include HRS-7058 capsules, HRS-7058 tablets, SHR-9839(sc), Adebali monoclonal antibody injection, Bevacizumab injection, and SHR-A2102 injection [1] Group 2: Industry Implications - The approval of these clinical trials reflects ongoing advancements in the biopharmaceutical sector, showcasing the company's commitment to expanding its therapeutic offerings [1] - The initiation of these trials may enhance the company's competitive position in the market, potentially leading to new revenue streams upon successful development and commercialization of the drugs [1]

Core Viewpoint - Heng Rui Medicine (01276.HK) has received approval from the National Medical Products Administration for clinical trials of Sulfate Emamectin Benzoate Tablets and SHR0302 Gel, aimed at treating vitiligo [1] Group 1: Company Developments - The company and its subsidiary, Ruishi Biopharmaceutical Co., Ltd., have been granted the Clinical Trial Approval Notice for the mentioned drugs [1] - The clinical trial applications for Sulfate Emamectin Benzoate Tablets and SHR0302 Gel were accepted on August 29, 2025, and have met the requirements for drug registration [1] Group 2: Product Information - The intended use for Sulfate Emamectin Benzoate Tablets is as a monotherapy or in combination with SHR0302 Gel for the treatment of vitiligo [1]

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of Sulfate Emamectin Benzoate Tablets and SHR0302 Gel, indicating progress in its drug development pipeline [1] Group 1: Drug Approvals and Clinical Trials - The company and its subsidiary, Ruishi Biopharmaceutical Co., Ltd., have been granted a clinical trial approval notice for Sulfate Emamectin Benzoate Tablets and SHR0302 Gel [1] - Sulfate Emamectin Benzoate Tablets have already been approved for four indications in China, including treatment for adult patients with active ankylosing spondylitis and moderate to severe rheumatoid arthritis who have had inadequate response to TNF inhibitors [1] Group 2: Drug Mechanism and Market Context - Sulfate Emamectin Benzoate is a highly selective JAK1 inhibitor that exerts anti-inflammatory and immunosuppressive effects by inhibiting JAK1 signaling [1] - Currently, there are no oral drugs of the same class approved globally for the treatment of vitiligo, although a topical drug, Ruxolitinib cream (OPZELURA®), has been approved, with no sales data available [1] Group 3: Research and Development Investment - The cumulative R&D investment for Sulfate Emamectin Benzoate projects has reached approximately 1.091 billion yuan [1]

Core Viewpoint - Heng Rui Medicine (01276.HK) has received approval from the National Medical Products Administration for multiple clinical trial applications, indicating a significant step forward in its drug development pipeline [1] Group 1: Company Developments - The company and its subsidiaries, including Suzhou Shengdiya Biopharmaceutical Co., Ltd., Shanghai Heng Rui Medicine Co., Ltd., and Shanghai Shengdi Medicine Co., Ltd., have been granted clinical trial approval for several products [1] - The approved products include HRS-7058 capsules, HRS-7058 tablets, SHR-9839(sc), Adebali monoclonal antibody injection, Bevacizumab injection, and SHR-A2102 injection [1] Group 2: Industry Implications - The approval of these clinical trials reflects ongoing advancements in the biopharmaceutical sector, showcasing the company's commitment to expanding its therapeutic offerings [1] - The initiation of these clinical trials may enhance the company's competitive position in the market, potentially leading to new revenue streams upon successful development and commercialization of the drugs [1]